ReviewPharmaceutical research2013
Drug delivery systems for the treatment of ischemic stroke.
Review in Pharmaceutical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Therapeutic Mechanisms of Stem Cell-Derived Exosomes for Neurological Disorders: An Overview.Molecular neurobiology · 2026Review
- Secretome from Uterine Cervical Mesenchymal Stem Cells as a Protector of Neuronal Cells Against Oxidative Stress and Inflammation.Biomolecules · 2025Article
- Advances in Engineered Nanoparticles for the Treatment of Ischemic Stroke by Enhancing Angiogenesis.International journal of nanomedicine · 2024Review
- Ultrasound trapping and navigation of microrobots in the mouse brain vasculature.Nature communications · 2023Article
- VEGFA Isoforms as Pro-Angiogenic Therapeutics for Cerebrovascular Diseases.Biomolecules · 2023Review
- Anti-CHAC1 exosomes for nose-to-brain delivery of miR-760-3p in cerebral ischemia/reperfusion injury mice inhibiting neuron ferroptosis.Journal of nanobiotechnology · 2023Article
- Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.Neural regeneration research · 2022Review
- Article
- Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.International journal of nanomedicine · 2020Article
- Perlecan regulates pericyte dynamics in the maintenance and repair of the blood-brain barrier.The Journal of cell biology · 2019Article
- Pre-stroke surgery is not beneficial to normotensive rats undergoing sixty minutes of transient focal cerebral ischemia.PloS one · 2018Article
- Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Delivery of Hypoxia-Inducible Heme Oxygenase-1 Gene for Site-Specific Gene Therapy in the Ischemic Stroke Animal Model.Pharmaceutical research · 2016Article
- Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases.Expert review of neurotherapeutics · 2016Review
- Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements.AAPS PharmSciTech · 2015Review
- Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage.Scientific reports · 2015Article
- Polysaccharides from Angelica sinensis alleviate neuronal cell injury caused by oxidative stress.Neural regeneration research · 2014Article
- Niosomes of ascorbic acid and α-tocopherol in the cerebral ischemia-reperfusion model in male rats.BioMed research international · 2014Article
- Bisphenol A exposure pathways in early childhood: Reviewing the need for improved risk assessment models.Journal of exposure science & environmental epidemiologyReview
- Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.Journal of neurology and neurosurgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is the third leading cause of death in the United States. Reduced cerebral blood flow causes acute damage to the brain due to excitotoxicity, reactive oxygen species (ROS), and ischemia. Currently, the main treatment for stroke is to revive the blood flow by using thrombolytic agents. Reviving blood flow also causes ischemia-reperfusion (I/R) damage. I/R damage results from inflammation and apoptosis and can persist for days to weeks, increasing the infarct size. Drugs can be applied to stroke to intervene in the sub-acute and chronic phases. Chemical, peptide, and genetic therapies have been evaluated to reduce delayed damage to the brain. These drugs have different characteristics, requiring that delivery carriers be developed based on these characteristics. The delivery route is another important factor affecting the efficiency of drug delivery. Various delivery routes have been developed, such as intravenous injection, intranasal administration, and local direct injection to overcome the blood-brain-barrier (BBB). In this review, the delivery carriers and delivery routes for peptide and gene therapies are discussed and examples are provided. Combined with new drugs, drug delivery systems will eventually provide useful treatments for ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.